A Non-Hydrazine Monoamine Oxidase Inhibitor with Antihypertensive Properties

Abstract

In studies on 9 hypertensive patients, N-benzyl-N-methyl-2-propynylamine.HCl (MO-911) caused pronounced orthostatic lowering of blood pressure. Marked monoamine oxidase inhibition was shown by 4- to 11-fold increases in urinary tryptamine output. Effects were initiated by doses of 75 to 125 mg/day and persisted 2 weeks after drug cessation. Since the drug''s structure differs from that of other inhibitors, the findings support the hypothesis that effective inhibition of monoamine oxidase produces hypotensive effects.